Back to Search Start Over

Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

Authors :
Himanshu P. Upadhyaya
Jenny Y. Chien
Amanda J. Long
Martin S. Bohm
Nicole L. Kallewaard
Lisa F. Macpherson
Dipak R. Patel
Matthew M. Hufford
Constance J. Krull
Jocelyn Y. Ang
Peter Chen
William J. Muller
Jeffrey A. Potts
Timothy Quinn
Mark Williams
BLAZE-1 Investigators
Source :
Infectious Diseases and Therapy, Vol 12, Iss 7, Pp 1861-1873 (2023)
Publication Year :
2023
Publisher :
Adis, Springer Healthcare, 2023.

Abstract

Abstract Introduction Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present pharmacokinetic (PK), efficacy, and safety results from pediatric participants ( 12 to

Details

Language :
English
ISSN :
21938229 and 21936382
Volume :
12
Issue :
7
Database :
Directory of Open Access Journals
Journal :
Infectious Diseases and Therapy
Publication Type :
Academic Journal
Accession number :
edsdoj.4a8e4f959324473bb550800f3098224f
Document Type :
article
Full Text :
https://doi.org/10.1007/s40121-023-00832-y